Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

ETV6 (ETS Variant Transcription Factor 6)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

ETV6-NTRK3 fusion	Acute Lymphocytic Leukemia	ETV6-NTRK3 fusion	Acute Lymphocytic Leukemia	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
ETV6-NTRK3 fusion	Head and Neck Cancer	ETV6-NTRK3 fusion	Head and Neck Cancer	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
ETV6-NTRK3 fusion	Solid Tumor	ETV6-NTRK3 fusion	Solid Tumor	entrectinib Sensitive: C3 – Early Trials entrectinib Sensitive : C3	entrectinib Sensitive: C3 – Early Trials entrectinib Sensitive : C3
ETV6-NTRK3 fusion	Salivary Gland Cancer	ETV6-NTRK3 fusion	Salivary Gland Cancer	entrectinib Resistant: C3 – Early Trials entrectinib Resistant : C3	entrectinib Resistant: C3 – Early Trials entrectinib Resistant : C3
ETV6-NTRK3 fusion	Acute Myelogenous Leukemia	ETV6-NTRK3 fusion	Acute Myelogenous Leukemia	entrectinib Sensitive: C3 – Early Trials entrectinib Sensitive : C3	entrectinib Sensitive: C3 – Early Trials entrectinib Sensitive : C3
ETV6 amplification	Nasopharyngeal Carcinoma	ETV6 amplification	Nasopharyngeal Carcinoma	toripalimab-tpzi Resistant: C3 – Early Trials toripalimab-tpzi Resistant : C3	toripalimab-tpzi Resistant: C3 – Early Trials toripalimab-tpzi Resistant : C3
ETV6-NTRK3 fusion	Salivary Gland Cancer	ETV6-NTRK3 fusion	Salivary Gland Cancer	larotrectinib Sensitive: C3 – Early Trials larotrectinib Sensitive : C3	larotrectinib Sensitive: C3 – Early Trials larotrectinib Sensitive : C3
ETV6 mutation	Lymphoma	ETV6 mutation	Lymphoma	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3
ETV6-NTRK3 fusion	Fibrosarcoma	ETV6-NTRK3 fusion	Fibrosarcoma	Resistant: C4 – Case Studies Resistant : C4	Resistant: C4 – Case Studies Resistant : C4
ETV6-NTRK3 fusion	Fibrosarcoma	ETV6-NTRK3 fusion	Fibrosarcoma	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4
ETV6-NTRK3 fusion	Fibrosarcoma	ETV6-NTRK3 fusion	Fibrosarcoma	vincristine + dactinomycin Resistant: C4 – Case Studies vincristine + dactinomycin Resistant : C4	vincristine + dactinomycin Resistant: C4 – Case Studies vincristine + dactinomycin Resistant : C4
ETV6-NTRK3 fusion	Breast Cancer	ETV6-NTRK3 fusion	Breast Cancer	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4